The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor.
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
DNA Damage
/ drug effects
Down-Regulation
/ drug effects
Fanconi Anemia Complementation Group D2 Protein
/ genetics
Female
Forkhead Box Protein M1
/ antagonists & inhibitors
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Immunohistochemistry
/ methods
Infant
Male
Nuclear Proteins
/ genetics
Prognosis
RNA, Messenger
/ genetics
RNA, Small Interfering
/ genetics
Rhabdoid Tumor
/ drug therapy
Survival Rate
Thiostrepton
/ pharmacology
Cell cycle
FANCD2
FOXM1
Malignant rhabdoid tumor
NBS1
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
25
08
2020
accepted:
22
10
2020
pubmed:
23
11
2020
medline:
13
4
2021
entrez:
22
11
2020
Statut:
ppublish
Résumé
Malignant rhabdoid tumor (MRT) is a rare, highly aggressive sarcoma with an uncertain cell of origin. Despite the existing standard of intensive multimodal therapy, the prognosis of patients with MRT is very poor. Novel antitumor agents are needed for MRT patients. Forkhead box transcription factor 1 (FOXM1) is overexpressed and is correlated with the pathogenesis in several human malignancies. In this study, we identified the clinicopathological and prognostic values of the expression of FOXM1 and its roles in the progression of MRT. We investigated the FOXM1 expression levels and their clinical significance in 23 MRT specimens using immunohistochemistry and performed clinicopathologic and prognostic analyses. We also demonstrated correlations between the downregulation of FOXM1 and oncological characteristics using small interfering RNA (siRNA) and FOXM1 inhibitor in MRT cell lines. Histopathological analyses revealed that primary renal MRTs showed significantly low FOXM1 protein expression levels (p = 0.032); however, there were no significant differences in other clinicopathological characteristics or the survival rate. FOXM1 siRNA and FOXM1 inhibitor (thiostrepton) successfully downregulated the mRNA and protein expression of FOXM1 in vitro and the downregulation of FOXM1 inhibited cell proliferation, drug resistance to chemotherapeutic agents, migration, invasion, and caused the cell cycle arrest and apoptosis of MRT cell lines. A cDNA microarray analysis showed that FOXM1 regulated FANCD2 and NBS1, which are key genes for DNA damage repair. This study demonstrates that FOXM1 may serve as a promising therapeutic target for MRT.
Identifiants
pubmed: 33221995
doi: 10.1007/s00432-020-03438-w
pii: 10.1007/s00432-020-03438-w
doi:
Substances chimiques
Antineoplastic Agents
0
FOXM1 protein, human
0
Fanconi Anemia Complementation Group D2 Protein
0
Forkhead Box Protein M1
0
Nuclear Proteins
0
RNA, Messenger
0
RNA, Small Interfering
0
Thiostrepton
HR4S203Y18
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1499-1518Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP19H03444
Références
Abuzeid WM, Jiang X, Shi G et al (2009) Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest 119:1974–1985. https://doi.org/10.1172/JCI33816
doi: 10.1172/JCI33816
pubmed: 19487811
pmcid: 2701852
Beckwith JB, Palmer NF (1978) Histopathology and prognosis of Wilms tumor results from the first National Wilms’ tumor study. Cancer 41:1937–1948. https://doi.org/10.1002/1097-0142(197805)41:5%3c1937::AID-CNCR2820410538%3e3.0.CO;2-U
doi: 10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO;2-U
pubmed: 206343
Biegel JA, Zhou JY, Rorke LB et al (1999) Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59:74–79
pubmed: 9892189
Carr JR, Park HJ, Wang Z et al (2010) FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70:5054–5063. https://doi.org/10.1158/0008-5472.CAN-10-0545
doi: 10.1158/0008-5472.CAN-10-0545
pubmed: 20530690
pmcid: 2893542
Chi SN, Zimmerman MA, Yao X et al (2009) Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 27:385–389. https://doi.org/10.1200/JCO.2008.18.7724
doi: 10.1200/JCO.2008.18.7724
pubmed: 19064966
pmcid: 2645855
Chirnomas D, Taniguchi T, De La Vega M et al (2006) Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 5:952–961. https://doi.org/10.1158/1535-7163.MCT-05-0493
doi: 10.1158/1535-7163.MCT-05-0493
pubmed: 16648566
Chiu WT, Huang YF, Tsai HY et al (2015) FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget 6:2349–2365. https://doi.org/10.18632/oncotarget.2957
doi: 10.18632/oncotarget.2957
pubmed: 25537512
Christensen L, Joo J, Lee S et al (2013) FOXM1 is an oncogenic mediator in Ewing sarcoma. PLoS ONE 8:1–7. https://doi.org/10.1371/journal.pone.0054556
doi: 10.1371/journal.pone.0054556
de Moraes GN, Delbue D, Silva KL et al (2015) FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance. Cell Signal 27:2496–2505. https://doi.org/10.1016/j.cellsig.2015.09.013
doi: 10.1016/j.cellsig.2015.09.013
Engeland K (2018) Cell cycle arrest through indirect transcriptional repression by p53: i have a DREAM. Cell Death Differ 25:114–132. https://doi.org/10.1038/cdd.2017.172
doi: 10.1038/cdd.2017.172
pubmed: 29125603
Gao R, Singh R, Kaul Z et al (2015) Targeting of DNA damage signaling pathway induced senescence and reduced migration of cancer cells. J Gerontol Ser A Biol Sci Med Sci 70:701–713. https://doi.org/10.1093/gerona/glu019
doi: 10.1093/gerona/glu019
Gartel AL (2008) FoxM1 inhibitors as potential anticancer drugs. Expert Opin Ther Targets 12:663–665
doi: 10.1517/14728222.12.6.663
Geller JI, Roth JJ, Biegel JA (2015) Biology and treatment of rhabdoid tumor. Crit Rev Oncog 20:199–216. https://doi.org/10.1615/CritRevOncog.2015013566
doi: 10.1615/CritRevOncog.2015013566
pubmed: 26349416
pmcid: 6087667
Ginn KF, Gajjar A (2012) Atypical teratoid rhabdoid tumor: current therapy and future directions. Front Oncol 2:1–13. https://doi.org/10.3389/fonc.2012.00114
doi: 10.3389/fonc.2012.00114
Grant GD, Brooks L, Zhang X et al (2013) Identification of cell cycle-regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors. Mol Biol Cell 24:3634–3650. https://doi.org/10.1091/mbc.E13-05-0264
doi: 10.1091/mbc.E13-05-0264
pubmed: 24109597
pmcid: 3842991
Grompe M (2001) Fanconi anemia and DNA repair. Hum Mol Genet 10:2253–2259. https://doi.org/10.1093/hmg/10.20.2253
doi: 10.1093/hmg/10.20.2253
pubmed: 11673408
Gu C, Jing X, Holman C et al (2019) Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer 19:1238. https://doi.org/10.1186/s12885-019-6443-1
doi: 10.1186/s12885-019-6443-1
pubmed: 31862002
pmcid: 6923850
Halasi M, Gartel AL (2009) A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle 8:1966–1967. https://doi.org/10.4161/cc.8.12.8708
doi: 10.4161/cc.8.12.8708
pubmed: 19411834
Hasselblatt M, Gesk S, Oyen F et al (2011) Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol 35:933–935. https://doi.org/10.1097/PAS.0b013e3182196a39
doi: 10.1097/PAS.0b013e3182196a39
pubmed: 21566516
Helleday T, Lo J, van Gent DC, Engelward BP (2007) DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 6:923–935. https://doi.org/10.1016/j.dnarep.2007.02.006
doi: 10.1016/j.dnarep.2007.02.006
Ho V, Chung L, Singh A et al (2018) Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis. BMC Cancer 18:1–11. https://doi.org/10.1186/s12885-018-4776-9
doi: 10.1186/s12885-018-4776-9
Hou Y, Zhu Q, Li Z et al (2017) The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. Cell Death Dis 8:e2659–e2711. https://doi.org/10.1038/cddis.2017.53
doi: 10.1038/cddis.2017.53
pubmed: 28277541
pmcid: 5386553
Ito T, Kohashi K, Yamada Y et al (2016a) Prognostic significance of Forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in angiosarcoma. J Cancer 7:823–830. https://doi.org/10.7150/jca.14461
doi: 10.7150/jca.14461
pubmed: 27162541
pmcid: 4860799
Ito T, Kohashi K, Yamada Y et al (2016b) Prognostic significance of forkhead box M1 (FoxM1) expression and antitumour effect of FoxM1 inhibition in melanoma. Histopathology 69:63–71. https://doi.org/10.1111/his.12909
doi: 10.1111/his.12909
pubmed: 26619071
Kalin TV, Wang I-C, Ackerson TJ, Major ML, Detrisac CJ, Kalinichenko VV, Alexander LRHC (2006) Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 66:1712–1720
doi: 10.1158/0008-5472.CAN-05-3138
Kalinichenko VV, Major ML, Wang X et al (2004) Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 18:830–850. https://doi.org/10.1101/gad.1200704
doi: 10.1101/gad.1200704
pubmed: 15082532
pmcid: 387422
Khan I, Halasi M, Patel A et al (2018) FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI insight 3:1–17. https://doi.org/10.1172/jci.insight.121583
doi: 10.1172/jci.insight.121583
Khongkow P, Karunarathna U, Khongkow M et al (2014) FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene 33:4144–4155. https://doi.org/10.1038/onc.2013.457
doi: 10.1038/onc.2013.457
pubmed: 24141789
Kim KH, Roberts CWM (2014) Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genet 207:365–372. https://doi.org/10.1016/j.cancergen.2014.04.004
doi: 10.1016/j.cancergen.2014.04.004
pubmed: 24853101
pmcid: 4195815
Kim IM, Ackerson T, Ramakrishna S et al (2006) The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 66:2153–2161. https://doi.org/10.1158/0008-5472.CAN-05-3003
doi: 10.1158/0008-5472.CAN-05-3003
pubmed: 16489016
Komatsu H, Masuda T, Iguchi T et al (2017) Clinical significance of fancd2 gene expression and its association with tumor progression in hepatocellular carcinoma. Anticancer Res 37:1083–1090. https://doi.org/10.21873/anticanres.11420
doi: 10.21873/anticanres.11420
pubmed: 28314268
Kuda M, Kohashi K, Yamada Y et al (2016) FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target. Tumour Biol 37:5213–5223. https://doi.org/10.1007/s13277-015-4351-9
doi: 10.1007/s13277-015-4351-9
pubmed: 26553361
Kuo K-T, Chou T-Y, Hsu H-S et al (2012) Prognostic significance of NBS1 and snail expression in esophageal squamous cell carcinoma. Ann Surg Oncol 19:549–557. https://doi.org/10.1245/s10434-011-2043-2
doi: 10.1245/s10434-011-2043-2
Kwok JMM, Myatt SS, Marson CM et al (2008) Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther 7:2022–2032. https://doi.org/10.1158/1535-7163.MCT-08-0188
doi: 10.1158/1535-7163.MCT-08-0188
pubmed: 18645012
Kwok JMM, Peck B, Monteiro LJ et al (2010) FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 8:24–34. https://doi.org/10.1158/1541-7786.MCR-09-0432
doi: 10.1158/1541-7786.MCR-09-0432
pubmed: 20068070
pmcid: 2809047
Laoukili J, Kooistra MRH, Brás A et al (2005) FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7:126–136. https://doi.org/10.1038/ncb1217
doi: 10.1038/ncb1217
pubmed: 15654331
Leon-Galicia I, Diaz-Chavez J, Albino-Sanchez ME et al (2018) Resveratrol decreases Rad51 expression and sensitizes cisplatin-resistant MCF-7 breast cancer cells. Oncol Rep 39:3025–3033. https://doi.org/10.3892/or.2018.6336
doi: 10.3892/or.2018.6336
pubmed: 29620223
Li D, Ye L, Lei Y et al (2019) Downregulation of FoxM1 sensitizes nasopharyngeal carcinoma cells to cisplatin via inhibition of MRN-ATM-mediated DNA repair. BMB Rep 52:208–213. https://doi.org/10.5483/BMBRep.2019.52.3.249
doi: 10.5483/BMBRep.2019.52.3.249
pubmed: 30638177
pmcid: 6476488
Liang CC, Li Z, Lopez-Martinez D et al (2016) The FANCD2-FANCI complex is recruited to DNA interstrand crosslinks before monoubiquitination of FANCD2. Nat Commun 7:1–10. https://doi.org/10.1038/ncomms12124
doi: 10.1038/ncomms12124
Liu M, Dai B, Kang SH et al (2006) FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 66:3593–3602. https://doi.org/10.1158/0008-5472.CAN-05-2912
doi: 10.1158/0008-5472.CAN-05-2912
pubmed: 16585184
Liu Y, Chen X, Gu Y et al (2015) FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway. Neoplasma 62:61–71. https://doi.org/10.4149/neo_2015_008
doi: 10.4149/neo_2015_008
pubmed: 25563368
Liu C, Shi J, Li Q et al (2019) STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer. Clin Sci 133:645–663. https://doi.org/10.1042/CS20180816
doi: 10.1042/CS20180816
pmcid: 6395369
Ma RYM, Tong THK, Leung WY, Yao KM (2010) Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1. Methods Mol Biol 647:113–123. https://doi.org/10.1007/978-1-60761-738-9_6
doi: 10.1007/978-1-60761-738-9_6
Madureira PA, Varshochi R, Constantinidou D et al (2006) The forkhead box M1 protein regulates the transcription of the estrogen receptor α in breast cancer cells. J Biol Chem 281:25167–25176. https://doi.org/10.1074/jbc.M603906200
doi: 10.1074/jbc.M603906200
pubmed: 16809346
Maekawa A, Kohashi K, Kuda M et al (2016) Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas. BMC Cancer 16:1–12. https://doi.org/10.1186/s12885-016-2542-4
doi: 10.1186/s12885-016-2542-4
Maekawa A, Kohashi K, Setsu N et al (2016) Expression of Forkhead box M1 in soft tissue leiomyosarcoma: clinicopathologic and in vitro study using a newly established cell line. Cancer Sci 107:95–102. https://doi.org/10.1111/cas.12846
doi: 10.1111/cas.12846
pubmed: 26560505
pmcid: 4724818
Major ML, Lepe R, Costa RH (2004) Forkhead Box M1B transcriptional activity requires binding of Cdk-Cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol 24:2649–2661. https://doi.org/10.1128/mcb.24.7.2649-2661.2004
doi: 10.1128/mcb.24.7.2649-2661.2004
pubmed: 371108
pmcid: 371108
Masliah-Planchon J, Bièche I, Guinebretière J-M et al (2015) SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol Mech Dis 10:145–171
doi: 10.1146/annurev-pathol-012414-040445
Metselaar DS, Meel MH, Benedict B et al (2019) Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. EBioMedicine 50:81–92. https://doi.org/10.1016/j.ebiom.2019.10.062
doi: 10.1016/j.ebiom.2019.10.062
pubmed: 31735550
pmcid: 6921187
Monteiro LJ, Khongkow P, Kongsema M et al (2013) The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene 32:4634–4645. https://doi.org/10.1038/onc.2012.491
doi: 10.1038/onc.2012.491
pubmed: 23108394
Nakanishi K, Taniguchi T, Ranganathan V et al (2002) Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell Biol 4:913–920. https://doi.org/10.1038/ncb879
doi: 10.1038/ncb879
pubmed: 12447395
Nakashima S, Kobayashi S, Nagano H et al (2015) BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. Cancer Sci 106:584–591. https://doi.org/10.1111/cas.12652
doi: 10.1111/cas.12652
pubmed: 25736055
pmcid: 4452159
Narita T, Taga T, Sugita K et al (2001) The autocrine loop of epidermal growth factor receptor-epidermal growth factor/transforming growth factor-α in malignant rhabdoid tumor cell lines: heterogeneity of autocrine mechanism in TTC549. Japanese J Cancer Res 92:269–278. https://doi.org/10.1111/j.1349-7006.2001.tb01091.x
doi: 10.1111/j.1349-7006.2001.tb01091.x
Nepal M, Che R, Ma C et al (2017) FANCD2 and DNA damage. Int J Mol Sci 18:1–9. https://doi.org/10.3390/ijms18081804
doi: 10.3390/ijms18081804
Nicolaou KC, Zak M, Rahimipour S et al (2005) Discovery of a biologically active thiostrepton fragment. J Am Chem Soc 127:15042–15044. https://doi.org/10.1021/ja0552803
doi: 10.1021/ja0552803
pubmed: 16248640
Okada K, Fujiwara Y, Takahashi T et al (2013) Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol 20:1035–1043. https://doi.org/10.1245/s10434-012-2680-0
doi: 10.1245/s10434-012-2680-0
pubmed: 23054116
Palle K, Vaziri C (2011) Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA topoisomerase 1 inhibition. Cell Cycle 10:1625–1638. https://doi.org/10.4161/cc.10.10.15617
doi: 10.4161/cc.10.10.15617
pubmed: 21478670
pmcid: 3127162
Park HJ, Gusarova G, Wang Z et al (2011) Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med 3:21–34. https://doi.org/10.1002/emmm.201000107
doi: 10.1002/emmm.201000107
pubmed: 21204266
pmcid: 3401999
Park YY, Jung SY, Jennings NB et al (2012) FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33:1843–1853. https://doi.org/10.1093/carcin/bgs167
doi: 10.1093/carcin/bgs167
pubmed: 22581827
pmcid: 3529559
Peng WX, Han X, Zhang CL et al (2017) FoxM1-mediated RFC5 expression promotes temozolomide resistance. Cell Biol Toxicol 33:527–537. https://doi.org/10.1007/s10565-017-9381-1
doi: 10.1007/s10565-017-9381-1
pubmed: 28185110
Pilarsky C, Wenzig M, Specht T et al (2004) Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 6:744–750. https://doi.org/10.1593/neo.04277
doi: 10.1593/neo.04277
pubmed: 15720800
pmcid: 1531678
Raychaudhuri P, Park HJ (2011) FoxM1: a master regulator of tumor metastasis. Cancer Res 71:4329–4333. https://doi.org/10.1158/0008-5472.CAN-11-0640
doi: 10.1158/0008-5472.CAN-11-0640
pubmed: 21712406
pmcid: 3129416
Ren L, Chen L, Wu W et al (2017) Potential biomarkers of DNA replication stress in cancer. Oncotarget 8:36996–37008. https://doi.org/10.18632/oncotarget.16940
doi: 10.18632/oncotarget.16940
pubmed: 28445142
pmcid: 5514887
Roberts CWM, Orkin SH (2004) The SWI/SNF complex—chromatin and cancer. Nat Rev Cancer 4:133–142. https://doi.org/10.1038/nrc1273
doi: 10.1038/nrc1273
pubmed: 14964309
Roh YG, Mun MH, Jeong MS et al (2018) Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1. BMB Rep 51:98–103. https://doi.org/10.5483/BMBRep.2018.51.2.222
doi: 10.5483/BMBRep.2018.51.2.222
pubmed: 29397866
pmcid: 5836564
Roh YG, Mun JY, Kim SK et al (2020) Fanconi anemia pathway activation by foxm1 is critical to bladder cancer recurrence and anticancer drug resistance. Cancers (Basel) 12:1–20. https://doi.org/10.3390/cancers12061417
doi: 10.3390/cancers12061417
Schneppenheim R, Frühwald MC, Gesk S et al (2010) Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 86:279–284. https://doi.org/10.1016/j.ajhg.2010.01.013
doi: 10.1016/j.ajhg.2010.01.013
pubmed: 20137775
pmcid: 2820190
Smirnov A, Panatta E, Lena AM et al (2016) FOXM1 regulates proliferation, senescence and oxidative stress in keratinocytes and cancer cells. Aging (Albany NY) 8:1384–1397. https://doi.org/10.18632/aging.100988
doi: 10.18632/aging.100988
Su WP, Ho YC, Wu CK et al (2017) Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways. Sci Rep 7:1–15. https://doi.org/10.1038/s41598-017-04223-5
doi: 10.1038/s41598-017-04223-5
Sultan I, Qaddoumi I, Rodriguez-Galindo C et al (2010) Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors. Pediatr Blood Cancer 54:35–40. https://doi.org/10.1002/pbc.22285
doi: 10.1002/pbc.22285
pubmed: 19798737
Tan Y, Raychaudhuri P, Costa RH (2007) Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol 27:1007–1016. https://doi.org/10.1128/mcb.01068-06
doi: 10.1128/mcb.01068-06
pubmed: 17101782
Taniguchi T, Garcia-Higuera I, Xu B et al (2002) Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109:459–472. https://doi.org/10.1016/S0092-8674(02)00747-X
doi: 10.1016/S0092-8674(02)00747-X
pubmed: 12086603
Tassi RA, Todeschini P, Siegel ER et al (2017) FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. J Exp Clin Cancer Res 36:1–18. https://doi.org/10.1186/s13046-017-0536-y
doi: 10.1186/s13046-017-0536-y
Teh MT, Wong ST, Neill GW et al (2002) FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 62:4773–4780
pubmed: 12183437
Tian L, Zhao Z, Xie L, Zhu JP (2018) MiR-361–5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarget 9:4886–4896. https://doi.org/10.18632/oncotarget.23513
doi: 10.18632/oncotarget.23513
pubmed: 29435149
Tomlinson GE, Breslow NE, Dome J et al (2005) Rhabdoid tumor of the kidney in the National Wilms’ Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol 23:7641–7645. https://doi.org/10.1200/JCO.2004.00.8110
doi: 10.1200/JCO.2004.00.8110
pubmed: 16234525
Uddin S, Ahmed M, Hussain A et al (2011) Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol 178:537–547. https://doi.org/10.1016/j.ajpath.2010.10.020
doi: 10.1016/j.ajpath.2010.10.020
pubmed: 21281787
pmcid: 3070566
van den Heuvel-Eibrink MM, van Tinteren H, Rehorst H et al (2011) Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group. Pediatr Blood Cancer 56:733–737. https://doi.org/10.1002/pbc.22922
doi: 10.1002/pbc.22922
pubmed: 21370404
Versteege I, Sevenet N, Lange J, Rousseau-Merck M-F, Ambros P, Handgretinger Rt, Airias A, Delattre O (1998) Truncating mutations of hSNF5/INI1 in aggressive paedeatric cancer. Nature 394:203–206
doi: 10.1038/28212
Wan LY, Deng J, Xiang XJ et al (2015) miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun 457:125–132. https://doi.org/10.1016/j.bbrc.2014.11.039
doi: 10.1016/j.bbrc.2014.11.039
pubmed: 25446103
Wang X, Haswell JR, CMWR (2014) Molecular pathways: SWI/SNF(BAF) complexes are frequently mutated in cancer—mechanisms and potential therapeutic insights. Clin Cancer Res 20:21–27. https://doi.org/10.1158/1078-0432
doi: 10.1158/1078-0432
pubmed: 24122795
Wang I-C, Chen Y-J, Hughes D et al (2005) Forkhead Box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) Ubiquitin Ligase. Mol Cell Biol 25:10875–10894. https://doi.org/10.1128/mcb.25.24.10875-10894.2005
doi: 10.1128/mcb.25.24.10875-10894.2005
pubmed: 16314512
pmcid: 1316960
Wang Y, Wiltshire T, Senft J et al (2006) Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven. Mol Cancer Ther 5:3153–3161. https://doi.org/10.1158/1535-7163.MCT-06-0427
doi: 10.1158/1535-7163.MCT-06-0427
pubmed: 17172419
Wang Z, Banerjee S, Kong D et al (2007) Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 67:8293–8300. https://doi.org/10.1158/0008-5472.CAN-07-1265
doi: 10.1158/0008-5472.CAN-07-1265
pubmed: 17804744
Wang I-C, Chen Y-J, Hughes DE et al (2008) FoxM1 regulates transcription of JNK1 to promote the G 1 /S transition and tumor cell invasiveness. J Biol Chem 283:20770–20778. https://doi.org/10.1074/jbc.M709892200
doi: 10.1074/jbc.M709892200
pubmed: 18524773
pmcid: 2475715
Weeks DA, Beckwith JB, Mierau GW, Luckey DW (1989) Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms’ Tumor Study Pathology Center. Am J Surg Pathol 13:439–458
doi: 10.1097/00000478-198906000-00001
Westhoff GL, Chen Y, Teng NNH (2017) Targeting foxm1 improves cytotoxicity of paclitaxel and cisplatinum in platinum-resistant ovarian cancer. Int J Gynecol Cancer 27:887–894. https://doi.org/10.1097/IGC.0000000000000969
doi: 10.1097/IGC.0000000000000969
pubmed: 28498253
Wierstra I, Alves J (2007) FOXM1, a typical proliferation-associated transcription factor. Biol Chem 388:1257–1274. https://doi.org/10.1515/BC.2007.159
doi: 10.1515/BC.2007.159
pubmed: 18020943
Wonsey DR, Follettie MT (2005) Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 65:5181–5189. https://doi.org/10.1158/0008-5472.CAN-04-4059
doi: 10.1158/0008-5472.CAN-04-4059
pubmed: 15958562
Wu QF, Liu C, Tai MH et al (2010) Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol Sin 31:361–366. https://doi.org/10.1038/aps.2010.4
doi: 10.1038/aps.2010.4
pubmed: 20154714
pmcid: 4002417
Xia L, Mo P, Huang W et al (2012) The TNF-α/ROS/HIF-1-induced upregulation of foxMI expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis 33:2250–2259. https://doi.org/10.1093/carcin/bgs249
doi: 10.1093/carcin/bgs249
pubmed: 22831955
Xie T, Geng J, Wang Y, et al (2017) FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10 8:8574–8589
Xu K, Liu X, Mao X et al (2015) MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem 35:499–515. https://doi.org/10.1159/000369715
doi: 10.1159/000369715
pubmed: 25613903
Ye Q, Chen L, Yin X et al (2014) Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathol Oncol Res 20:931–938. https://doi.org/10.1007/s12253-014-9776-8
doi: 10.1007/s12253-014-9776-8
pubmed: 24752797
pmcid: 4177045
Yu J, Deshmukh H, Payton JE et al (2011) Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res 17:1924–1934. https://doi.org/10.1158/1078-0432.CCR-10-1551
doi: 10.1158/1078-0432.CCR-10-1551
pubmed: 21325289
Zhang N, Wu X, Yang L et al (2012) FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res 18:5961–5971. https://doi.org/10.1158/1078-0432.CCR-12-0039
doi: 10.1158/1078-0432.CCR-12-0039
pubmed: 22977194
pmcid: 3639123
Zhang JR, Lu F, Lu T et al (2014) Inactivation of FoxM1 transcription factor contributes to curcumin-induced inhibition of survival, angiogenesis, and chemosensitivity in acute myeloid leukemia cells. J Mol Med 92:1319–1330. https://doi.org/10.1007/s00109-014-1198-2
doi: 10.1007/s00109-014-1198-2
pubmed: 25179295
Zhang C, Wang Y, Feng YF et al (2016) Gli1 promotes colorectal cancer metastasis in a Foxm1-dependent manner by activating EMT and PI3k-AKT signaling. Oncotarget 7:86134–86147
doi: 10.18632/oncotarget.13348
Zhu X, Xue L, Yao Y et al (2018) The FoxM1-ABCC4 axis mediates carboplatin resistance in human retinoblastoma Y-79 cells. Acta Biochim Biophys Sin (Shanghai) 50:914–920. https://doi.org/10.1093/abbs/gmy080
doi: 10.1093/abbs/gmy080